According to a recent LinkedIn post from Axonis Therapeutics, CEO Joanna Stanicka is scheduled to participate in a Biotech CEOs on the Frontlines panel at MassBio’s State of Possible Conference on March 26. The panel, which includes executives from Q32 Bio, City Therapeutics, and QurAlis and is moderated by an Endpoints News reporter, is set to focus on challenges in advancing novel therapeutic platforms.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights that Axonis intends to advance its KCC2 platform and a lead clinical program targeting epilepsy, pain, and other central nervous system disorders. For investors, this visibility at a high-profile industry conference may underscore the company’s strategic positioning in CNS therapeutics and could help build partnerships, attract talent, and support future fundraising efforts, though no specific clinical or financial milestones are mentioned.